HIGHLIGHTS
- who: Jim Alkas from the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden have published the article: Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project, in the Journal: (JOURNAL)
- what: The authors compared the risk of detected AKI among users of novel glucose-lowering drugs in Stockholmu00b4s routine healthcare.
- how: Against this background the authors conducted an observational study comparing risks of AKI among routine care users of novel glucose-lowering drugs in Stockholm (Fig 1).
- future . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.